Improved Survival in Liver Transplant Recipients Receiving Prolonged-Release Tacrolimus in the European Liver Transplant Registry.
Fiche publication
Date publication
février 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BACHELLIER Philippe, Pr MANTION Georges
Tous les auteurs :
Adam R, Karam V, Delvart V, Trunecka P, Samuel D, Bechstein WO, Nemec P, Tisone G, Klempnauer J, Rossi M, Rummo OO, Dokmak S, Krawczyk M, Pratschke J, Kollmar O, Boudjema K, Colledan M, Ericzon BG, Mantion G, Baccarani U, Neuhaus P, Paul A, Bachellier P, Zamboni F, Hanvesakul R, Muiesan P
Lien Pubmed
Résumé
This study was a retrospective analysis of the European Liver Transplant Registry (ELTR) performed to compare long-term outcomes with prolonged-release tacrolimus versus tacrolimus BD in liver transplantation (January 2008-December 2012). Clinical efficacy measures included univariate and multivariate analyses of risk factors influencing graft and patient survival at 3 years posttransplant. Efficacy measures were repeated using propensity score-matching for baseline demographics. Patients with
Référence
Am J Transplant. 2015 Feb 19